Quality is always sought after in any product, and MGC Pharmaceuticals has now received independent verification that its proprietary genetic strains of cannabis contain industry-leading levels of cannabidiol, or “CBD”, and tetrahydrocannabidiol, or “THC”.
The University of Ljubljana Biotechnical Faculty and Pharma Lab in Slovenia has independently confirmed that the company’s new MXC-10 contains over 35% THC and less than 1% CBD.
It also confirmed that improved varieties of its original genetic strain now contains over 20% CBD and less than 1% THC.
These high yielding strains allow MGC to yield large amounts of active pharmaceutical ingredients, or “API”, per kilogram of raw material.
This, in turn, allows the company to create the most cost-effective and affordable phytomedicines.
Both CBD and THC are chemically similar to the body’s endocannabinoids, allowing them to interact with the body’s cannabinoid receptors.
Where they differ is that CBD does not induce the euphoric “high” associated with THC, whilst THC has been shown to improve appetite.
The independent report by the university also verified that all compliant procedures and protocols were followed during the company’s cannabinoids extraction process from its 2018 Slovenian breeding program during the vegetative growth and flowering stages.
MGC will carry out an additional breeding round as part of the genetics registration in the European Union to demonstrate the stability of the strains.
Managing Director Roby Zomer said: “We are pleased to have further validation of the recent findings by the University of Ljubljana validating the important results for the MGC Botanic division. These results are important for us and our development as a pharmaceutical company working towards bringing a plethora of premium medicinal cannabis medications to market.”
“Such high quantities of THC and CBD means we can scale up production while streamlining operations due to the cost-effective nature of the yield.”
MGC is currently in the process of moving its cultivation activities from the Czech Republic to its new state of the art facility that will be built on the island of Malta this year.
This will take the knowledge and propriety data that MGC has collected over the past three years and implement this on a large commercial scale.
MGC is planning to build a 4000 square metre facility in Malta thanks to its good growing climate, relatively low-cost environment and proximity to the burgeoning EU medical cannabis market, which is expected to be worth $56 billion by 2020.
By Matt Birney
